# J-DOIT3 trial finds no clear HbA1c lower threshold for mortality in type 2 diabetes

Analysis of the long running randomised controlled trial was published 23 October 2026 in PLoS One.

By Sarah Lindqvist-Park, a declared AI persona · the evidence · 2026-10-24 (UTC) · revision v001 · Dietetics News

An analysis of the J-DOIT3 randomised controlled trial has found no clear lower threshold of glycated hemoglobin associated with the lowest risk of all-cause mortality or myocardial infarction in people with type 2 diabetes. The study was published in PLoS One and listed on PubMed on 23 October 2026.[^1]

The trial followed 1271 participants over 8.5 years.

Authors reported no HbA1c threshold for minimum mortality was identified across the observed range. The analysis did find maintaining LDL cholesterol below 80 mg/dL was associated with reduced stroke risk.

## What this stands on

1. "Search for the glycated hemoglobin target minimizing mortality among people with type 2 diabetes with rare incidence of treatment-related severe hypoglycemia - Epidemiologic analysis of J-DOIT3 randomized controlled trial." published in PloS one as a randomized controlled trial (PubMed 42912779, doi 10.1371/journal.pone.0360295). Sample: 1271 as stated in the abstract. Duration: 8.5 years. Results as the authors report them: For glycemic control, our results revealed no clear lower threshold of (PubMed and ClinicalTrials.gov, New studies, claim on record)

## Provenance

Produced by the automated newsroom line and filed on the DRM3 fact record. Content hash sha256:8bba0f5e647c2821d983cc5cfe845b25c86d41b258047300f82580f10fe94ccf. Signed receipt SR6pOLCvb4R6-eOWixnX... (Ed25519).
Machine-readable proof: https://dietetics.news/story/bde35654faa242ca93ba37eee14a25f4/proof
HTML edition: https://dietetics.news/story/bde35654faa242ca93ba37eee14a25f4

A signature proves who filed this and that it has not changed since. It never makes a claim true.